Search Result

Results for "

ATR inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ATM/ATR (51) AMPK (1) Amyloid-β (3) Apoptosis (11) Autophagy (1) Bacterial (3) BCL6 (1) CDK (5) Checkpoint Kinase (Chk) (1) CMV (3) DNA-PK (1) DNA/RNA Synthesis (4) Endogenous Metabolite (1) HBV (2) Hedgehog (2) HSV (4) Interleukin Related (1) Isotope-Labeled Compounds (2) JNK (3) MDM-2/p53 (1) mTOR (4) Nucleoside Antimetabolite/Analog (3) Orthopoxvirus (2) p38 MAPK (3) PARP (1) PD-1/PD-L1 (2) PI3K (1) PROTACs (2) Reference Standards (4) Reverse Transcriptase (1) Src (1) STAT (2) STING (2)
By Research Areas:	Cancer (63) Cardiovascular Disease (2) Infection (4) Inflammation/Immunology (5) Neurological Disease (3)

By Targets:

ATM/ATR (51)

AMPK (1)

Amyloid-β (3)

Apoptosis (11)

Autophagy (1)

Bacterial (3)

BCL6 (1)

CDK (5)

Checkpoint Kinase (Chk) (1)

CMV (3)

DNA-PK (1)

DNA/RNA Synthesis (4)

Endogenous Metabolite (1)

HBV (2)

Hedgehog (2)

HSV (4)

Interleukin Related (1)

Isotope-Labeled Compounds (2)

JNK (3)

MDM-2/p53 (1)

mTOR (4)

Nucleoside Antimetabolite/Analog (3)

Orthopoxvirus (2)

p38 MAPK (3)

PARP (1)

PD-1/PD-L1 (2)

PI3K (1)

PROTACs (2)

Reference Standards (4)

Reverse Transcriptase (1)

Src (1)

STAT (2)

STING (2)

By Research Areas:

Cancer (63)

Cardiovascular Disease (2)

Infection (4)

Inflammation/Immunology (5)

Neurological Disease (3)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: ATM/ATR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-111451

Tuvusertib M1774; ATR inhibitor 1	ATM/ATR	Cancer
Tuvusertib (M1774; ATR inhibitor 1) is a selective and orally active *ATR* inhibitor extracted from patent WO2015187451A1, compound I-l, with a K_i value below 1 μΜ .

HY-136270

Gartisertib 2 Publications Verification VX-803; M4344; ATR inhibitor 2	ATM/ATR	Cancer
Gartisertib (VX-803) is an ATP-competitive, orally active, and selective *ATR* inhibitor, with a K_i of <150 pM. Gartisertib potently inhibits ATR-driven phosphorylated checkpoint kinase-1 (Chk1) phosphorylation with an IC₅₀ of 8 nM. Antitumor activity .

HY-139609

Camonsertib RP-3500; ATR inhibitor 4	ATM/ATR mTOR	Cancer
Camonsertib (RP-3500) is an orally active, selective *ATR* kinase inhibitor (ATRi) with an IC₅₀ of 1.00 nM in biochemical assays. Camonsertib shows 30-fold selectivity for ATR over mTOR (IC₅₀=120 nM) and >2,000-fold selectivity over ATM, DNA-PK, and PI3Kα kinases. Camonsertib has potent antitumor activity .

HY-P10280

ATR kinase substrate peptide	ATM/ATR	Cancer
ATR kinase substrate peptide (compound 45) is a potent and selective inhibitor of *ATR* (Ataxia Telangiectasia and Rad3 related) protein kinase (K_i=6 nM). ATR kinase substrate peptide inhibits *ATR* activity by competing with *ATR* kinase ATP-binding sites to block *ATR* mediated signaling. ATR kinase substrate peptide can be used to study the role of *ATR* kinase in DNA damage response .

HY-172448

YY2201	ATM/ATR	Cancer
YY2201 is a highly potent and selective *ATR* inhibitor with an IC₅₀ of 8 nM. YY2201 shows >200-fold more selective for ATR than mTOR. YY2201 inhibits tumor progression in broad-spectrum cancer types (such as lung cancer) .

HY-149952

ATR-IN-23	ATM/ATR	Cancer
ATR-IN-23 (Compound 34) is a potent and selective *ATR* inhibitor with an IC₅₀ of 1.5 nM. ATR-IN-23 has potent antiproliferative effects on LoVo cells and synthetic lethality on HT-29 cells, and can be used in the study of DNA damage response (DDR)-deficient cancers .

HY-153462

ATR-IN-24	ATM/ATR	Cancer
ATR-IN-24 (Compound 1) is a *ATR* inhibitor. ATR-IN-24 has anticancer activity .

HY-147566

ATR-IN-14	ATM/ATR	Cancer
ATR-IN-14 (compound 1) is a potent *ATR* kinase inhibitor. ATR-IN-14 inhibits ATR signaling pathways downstream CHKI protein phosphorylation, with inhibition of 98.03% at 25 nM. ATR-IN-14 shows good anticancer activity in LoVo cells, with an IC₅₀ of 64 nM .

HY-153400

ATR-IN-22	ATM/ATR	Cancer
ATR-IN-22 (Compound 34) is an orally active *ATR* inhibitor. ATR-IN-22 inhibits MIAPaCa-2 proliferation (IC₅₀ <1 μM). ATR-IN-22 shows anti-tumor activity in colon cancer .

HY-147565

ATR-IN-13	ATM/ATR	Cancer
ATR-IN-13 (compound A9) is a potent *ATR* kinase inhibitor, with an IC₅₀ of 2 nM. ATR-IN-13 can be used for ATR kinase mediated diseases research, such as proliferative diseases and cancer .

HY-153729

ATR-IN-29	ATM/ATR	Cancer
ATR-IN-29 is a potent and orally active ATR kinase inhibitor with an IC₅₀ value of 1 nM. ATR-IN-29 shows antiproliferative activity .

HY-147190

ATR-IN-19	ATM/ATR	Cancer
ATR-IN-19 (Compound 15 R-configure) is an *ATR* inhibitor .

HY-147569

ATR-IN-17	ATM/ATR	Cancer
ATR-IN-17 (compound 88) is a potent *ATR* kinase inhibitor. ATR-IN-17 shows good anticancer activity in LoVo cells, with an IC₅₀ of 1 nM .

HY-147568

ATR-IN-16	ATM/ATR	Cancer
ATR-IN-16 (compound 46) is a potent *ATR* kinase inhibitor. ATR-IN-16 shows good anticancer activity in LoVo cells, with an IC₅₀ of 410 nM .

HY-P991272

ATR-107	Interleukin Related	Inflammation/Immunology
ATR-107 is a humanized monoclonal antibody inhibitor targeting interleukin-21 receptor (IL-21R). ATR-107 is promising for research of autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus .

HY-153393

ATR-IN-21	ATM/ATR	Cancer
ATR-IN-21 (compound 60) is a potent *ATR* inhibitor with an IC₅₀ value of <1000 nM .

HY-142671

ATR-IN-5	ATM/ATR	Cancer
ATR-IN-5 is a potent inhibitor of *ATR. ATR* is a class of protein kinases involved in genome stability and DNA damage repair, and is a member of the PIKK family. ATR-IN-5 has the potential for the research of ATR kinase-mediated diseases such as proliferative diseases and cancer (extracted from patent CN112047938A, compound D24) .

HY-142672

ATR-IN-6	ATM/ATR	Cancer
ATR-IN-6 is a potent inhibitor of *ATR. ATR* is a class of protein kinases involved in genome stability and DNA damage repair, and is a member of the PIKK family. ATR-IN-6 has the potential for the research of ATR kinase-mediated diseases such as proliferative diseases and cancer (extracted from patent WO2021233376A1, compound A22) .

HY-142924

ATR-IN-8	ATM/ATR	Cancer
ATR-IN-8 is a potent inhibitor of *ATR. ATR* is a key enzyme in the homologous recombination repair pathway and belongs to the PIKK family. ATR-IN-8 has the potential for the research of cancer diseases (extracted from patent WO2021143821A1, compound 3) .

HY-147570

ATR-IN-18	ATM/ATR	Cancer
ATR-IN-18 (compound 2) is an orally active and potent *ATR* kinase inhibitor, with an IC₅₀ of 0.69 nM. ATR-IN-18 shows antiproliferative activity in LoVo cells, with an IC₅₀ of 37.34 nM. ATR-IN-18 has anti-tumor activity .

HY-144436

ATR-IN-12	ATM/ATR	Cancer
ATR-IN-12 (Compound 5g) is a potent inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase with an IC₅₀ value of 0.007 μM. ATR-IN-12 displays good anti-tumor activity and significantly reduces the phosphorylation level of ATR and its downstream signaling protein. ATR-IN-12 is a promising lead compound for subsequent agent discovery targeting ATR kinase .

HY-144435

ATR-IN-11	ATM/ATR	Cancer
ATR-IN-11 (Compound Hit01) is a potent inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase. ATR kinase is a key regulating protein within the DNA damage response (DDR), responsible for sensing replication stress (RS). ATR-IN-11 is a promising lead compound for subsequent agent discovery targeting ATR kinase. ATR-IN-11 has the potential for the research of cancer disease .

HY-151915

ATR-IN-20	ATM/ATR mTOR	Cancer
ATR-IN-20 is a potent *ATR* (ATM/ATR) inhibitor with an IC₅₀ of 3 nM. ATR-IN-20 possess an inhibitory effect on mTOR (IC₅₀ of 18 nM) while displaying good selectivity against PI3Kα (100 nM), ATM (100 nM), and DNA-PK (662 nM). ATR-IN-20 exhibits excellent pharmacokinetic profile (F = 30%), and has anticancer effects .

HY-147567

ATR-IN-15	ATM/ATR DNA-PK PI3K	Cancer
ATR-IN-15 (compound 1) is an orally active and potent *ATR* kinase inhibitor, with an IC₅₀ of 8 nM. ATR-IN-15 also inhibits human colon tumor cells LoVo, DNA-PK and PI3K, with IC₅₀ values of 47, 663 and 5131 nM, respectively .

HY-161615

PROTAC ATR degrader-2	Apoptosis PROTACs	Cancer
PROTAC ATR degrader-2 (Compound 8i) is a PROTAC degrader for *ATR, through of . PROTAC ATR* degrader-2 degrades ATR in acute myeloid leukemia (AML) cells MV-4-11 and MOLM-13, with DC₅₀ of 22.9 and 34.5 nM. APROTAC ATR degrader-2 induces apoptosis, inhibits proliferations of AML cells. PROTAC ATR degrader-2 exhibits good pharmacokinetics charachers and antitumor efficacy against AML in mouse model. (Pink: ATR ligand (HY-161616); Blue:E3 ligase ligand Lenalidomide (HY-A0003); Black: linker)

HY-144214

ATR-IN-10	ATM/ATR	Cancer
ATR-IN-10 is a potent and highly selective inhibitor of ataxia telangiectasia mutated and Rad3-Related (ATR) kinase with an IC₅₀ value of 2.978 μM.

HY-169930

ATR kinase-IN-2	ATM/ATR	Cancer
ATR kinase-IN-2 (Compound I-G-27) is a ATR protein kinase inhibitor with the K_i of 0.01 ~ 1 μΜ and can be used for study of cancer .

HY-169931

ATR kinase-IN-3	ATM/ATR	Cancer
ATR kinase-IN-3 (Compound I-G-28) is a ATR protein kinase inhibitor with the K_i of 0.01 ~ 1 μΜ and can be used for study of cancer .

HY-145312

ATR-IN-4	ATM/ATR	Cancer
ATR-IN-4 is a potent *ATR* (Ataxia telangiectasia mutated gene Rad 3-associated kinase) inhibitor. ATR-IN-4 inhibits growth of human prostate cancer cells DU145 and human lung cancer cells NCI-H460 with IC₅₀s of 130.9 nM and 41 .33 nM, respectively. (Patent CN112142744A, compound 13) .

HY-174828

ATR/PARP1-IN-1	PARP ATM/ATR Apoptosis	Cancer
ATR/PARP1-IN-1 is a potent *ATR* and PARP1 dual inhibitor with IC₅₀s of 17.3 nM and 0.38 nM, respectively. ATR/PARP1-IN-1 effectively reduces cell viability, induces apoptosis and DNA damage. ATR/PARP1-IN-1 significantly impairs triple-negative breast cancer (TNBC) colony formation, migration, and invasion. ATR/PARP1-IN-1 suppresses tumor growth effectively in MDA-MB-468 xenografted mice, with no significant body weight change .

HY-145450

ATR-IN-9	ATM/ATR	Cancer
ATR-IN-9 is a potent inhibitor of Ataxia-telangiectasia and RAD-3-related protein kinase (ATR) extracted from patent WO2020087170A1, compound 59, has an IC₅₀ of 10 nM .

HY-15520

CGK733 5+ Cited Publications	ATM/ATR	Cancer
CGK733 is a potent *ATM/ATR* inhibitor, used for the research of cancer.

HY-19323

Ceralasertib Maximum Cited Publications 50 Publications Verification AZD6738	ATM/ATR	Cancer
Ceralasertib (AZD6738) is an orally active and bioavailable inhibitor of *ATR* kinase with an IC₅₀ of 1 nM.

HY-13816

NU6027	CDK ATM/ATR	Cancer
NU6027 is a potent and ATP-competitive inhibitor of both CDK1 and CDK2, with K_is of 2.5 μM and 1.3 μM, respectively. NU6027 is also a potent inhibitor of *ATR* and enhances hydroxyurea and cisplatin cytotoxicity in an ATR-dependent manner .

HY-13902

Berzosertib 15+ Cited Publications VE-822; VX-970; M6620	ATM/ATR	Cancer
Berzosertib (VE-822) is an *ATR* inhibitor with a K_i value of less than 0.2 nM. It also inhibits ATM with a K_i of 34 nM.

HY-15521

ETP-46464 2 Publications Verification	mTOR ATM/ATR	Cancer
ETP-46464 is an effective mTOR and *ATR* inhibitor with IC₅₀s of 0.6 and 14 nM, respectively.

HY-14731

VE-821 40+ Cited Publications	ATM/ATR	Cancer
VE-821 is a potent ATP-competitive inhibitor of *ATR* with K_i/IC₅₀ of 13 nM/26 nM.

HY-15557

AZ20 5+ Cited Publications	ATM/ATR	Cancer
AZ20 is a potent and selective inhibitor of *ATR* with an IC₅₀ of 5 nM, and has 8-fold selectivity against mTOR (IC₅₀=38 nM).

HY-19323A

(S)-Ceralasertib 2 Publications Verification (S)-AZD6738	ATM/ATR	Cancer
(S)-Ceralasertib ((S)-AZD6738) is the S-enantiomer of Ceralasertib (HY-19323). (S)-Ceralasertib is the inhibitor for ataxia telangiectasia mutated and rad3 related (ATR) .

HY-157941

ART0380	ATM/ATR	Cancer
ART0380 is a potent and selective *ATR* kinase inhibitor. ART0380 has selective antitumor activity that can be used for the research of Ataxia-Telangiectasia Mutated (ATM) aberrant cancers .

HY-161838

ICT10336	ATM/ATR	Cancer
ICT10336 is a hypoxia-responsive prodrug of ATR inhibitor, AZD6738 (HY-19323). ICT10336 is hypoxia-activated and specifically releases AZD6738 only in hypoxic conditions in vitro. This can inhibit *ATR* activation (T1989 and S428 phosphorylation) and subsequently abrogate HIF1a-mediated adaptation of hypoxic cancers cells, thus selectively inducing cell death in 2D and 3D cancer models. ICT10336 is a metabolic substrate of CYPOR activity.

HY-101566A

Elimusertib hydrochloride 10+ Cited Publications BAY 1895344 hydrochloride	ATM/ATR	Cancer
Elimusertib (BAY 1895344) hydrochloride is a potent, orally active and selective *ATR* inhibitor with an IC₅₀ of 7 nM. Elimusertib hydrochloride has anti-tumor activity . Elimusertib hydrochloride can be used for the research of solid tumors and lymphomas .

HY-101566S

Elimusertib-d3 BAY 1895344-d₃	ATM/ATR	Cancer
Elimusertib-d3 (BAY 1895344-d3) is the deuterium labeled Elimusertib (BAY 1895344). Elimusertib is a potent, orally active and selective ATR inhibitor and has anti-tumor activity .

HY-101566

Elimusertib 10+ Cited Publications BAY 1895344	ATM/ATR	Cancer
Elimusertib (BAY-1895344) is a potent, orally active and selective *ATR* inhibitor with an IC₅₀ of 7 nM. Elimusertib has anti-tumor activity . Elimusertib can be used for the research of solid tumors and lymphomas .

HY-123502

Ceralasertib formate AZD-6738 formate	ATM/ATR	Cancer
Ceralasertib formate is a potent, selective and orally active *ATR* inhibitor with an IC₅₀ value of 1 nM. Ceralasertib formate inhibits cell viability and induces DNA damage. Ceralasertib formate induces cell senescence. Ceralasertib formate shows antitumor activity .

HY-158345

PROTAC VHL-type degrader-1	PROTACs	Cancer
PROTAC VHL-type degrader-1 (compound 9b) is a VHL-type PROTAC degrader. PROTAC VHL-type degrader-1 induces ATM degradation synergistically enhancing the efficacy of ATR inhibitor AZD6738 .

HY-N7046

Silybin B Silibinin B	Amyloid-β Apoptosis JNK p38 MAPK	Neurological Disease Cancer
Silybin B (Silibinin B) is an orally active amyloid-β aggregation inhibitor and *ATR* pathway activator, that can cross the blood-brain barrier. Silybin B inhibits Aβ fibril formation and promotes amorphous aggregate formation, while activating the ATR-mediated DNA damage repair pathway and inhibiting JNK/p38 MAPK signaling. Silybin B can reduce Cisplatin (HY-17394)-induced neuronal DNA damage and apoptosis. Silybin B has anti-oxidative stress, cell cycle regulation and neuroprotective activities. Silybin B is mainly used in the study of Alzheimer's disease and Cisplatin chemotherapy-related neurotoxicity .

HY-159480

AD1058	Src ATM/ATR Apoptosis mTOR AMPK	Cancer
AD1058 is an orally active, selective, and BBB-permeable inhibitor of *ATR* (IC₅₀: 1.6 nM). AD1058 exhibits anticancer activity by inhibiting tumor cell proliferation, inducing cell cycle arrest, and promoting apoptosis. AD1058 is suitable for research on advanced malignancies and brain metastases .

HY-12016

KU-55933 45+ Cited Publications	ATM/ATR Autophagy	Cancer
KU-55933 is a potent ATM inhibitor with an IC₅₀ and K_i of 12.9 and 2.2 nM, respectively, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR.

HY-150617

Lartesertib M4076; ATM inhibitor-5	ATM/ATR STING PD-1/PD-L1	Cardiovascular Disease Inflammation/Immunology Cancer
Lartesertib (M4076) is an inhibitor of the serine/threonine protein kinase ATM with high potency. Lartesertib can inhibit the growth of multiple hematopoietic cell lines. Additionally, when combined with the ATR inhibitor Tuvusertib (HY-111451), Lartesertib can promote the death of tumor cells, activate the immune signaling pathway, and exhibit anti-tumor activity .

Cat. No.	Product Name	Target	Research Area

HY-P10280

ATR kinase substrate peptide	ATM/ATR	Cancer
ATR kinase substrate peptide (compound 45) is a potent and selective inhibitor of *ATR* (Ataxia Telangiectasia and Rad3 related) protein kinase (K_i=6 nM). ATR kinase substrate peptide inhibits *ATR* activity by competing with *ATR* kinase ATP-binding sites to block *ATR* mediated signaling. ATR kinase substrate peptide can be used to study the role of *ATR* kinase in DNA damage response .

Cat. No.	Product Name	Target	Research Area

HY-P991272

ATR-107	Interleukin Related	Inflammation/Immunology
ATR-107 is a humanized monoclonal antibody inhibitor targeting interleukin-21 receptor (IL-21R). ATR-107 is promising for research of autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N7046

Silybin B Silibinin B	Flavanonols Structural Classification Flavonoids Glycine soya Source classification Phenols Polyphenols Cyamopsis tetragonoloba (L.) Taub. Plants Compositae	Amyloid-β Apoptosis JNK p38 MAPK
Silybin B (Silibinin B) is an orally active amyloid-β aggregation inhibitor and *ATR* pathway activator, that can cross the blood-brain barrier. Silybin B inhibits Aβ fibril formation and promotes amorphous aggregate formation, while activating the ATR-mediated DNA damage repair pathway and inhibiting JNK/p38 MAPK signaling. Silybin B can reduce Cisplatin (HY-17394)-induced neuronal DNA damage and apoptosis. Silybin B has anti-oxidative stress, cell cycle regulation and neuroprotective activities. Silybin B is mainly used in the study of Alzheimer's disease and Cisplatin chemotherapy-related neurotoxicity .

HY-B0255

Adefovir dipivoxil 1 Publications Verification GS 0840	Infection Structural Classification Natural Products Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields Cancer	HBV Orthopoxvirus HSV DNA/RNA Synthesis ATM/ATR CDK
Adefovir dipivoxil is an orally active adenosine analog and Adefovir prodrug. Adefovir dipivoxil inhibits DNA synthesis, activates the *ATR* signaling pathway, and disrupts the KCTD12-CDK1 interaction. Adefovir dipivoxil has antiviral activity against PRV, HBV, and orthopoxviruses. Adefovir dipivoxil has inhibitory effects on both lamivudine-resistant and wild-type strains. Adefovir dipivoxil has antitumor activity against lung and colon cancer .

HY-N6954

Garcinone C 2 Publications Verification	Structural Classification other families Xanthones Classification of Application Fields Garcinia oblongifolia Champ. ex Benth. Guttiferae Source classification Phenols Polyphenols Plants Disease Research Fields Cancer	ATM/ATR STAT CDK Hedgehog
Garcinone C, a xanthone derivative, is a natural compound extracted from Garcinia oblongifolia that is used as an anti-inflammatory, astringency and granulation-promoting medicine, and has potential cytotoxic effects on certain cancers. Garcinone C stimulates the expression levels of *ATR* and 4E-BP1, arrests the cell cycle, inhibits cell viability of the human Nasopharyngeal carcinoma (NPC) cell lines CNE1, CNE2, HK1 and HONE1 in a time‑ and dose‑dependent manner through inhibition of Hedgehog signaling pathway. Garcinone C is orally active .

HY-N7046R

Silybin B (Standard) Silibinin B (Standard)	Flavanonols Structural Classification Flavonoids Glycine soya Source classification Phenols Polyphenols Cyamopsis tetragonoloba (L.) Taub. Plants Compositae	Reference Standards JNK Amyloid-β p38 MAPK Apoptosis
Silybin (Silibinin B) (Standard) is the analytical standard of Silybin B (HY-N7046). This product is intended for research and analytical applications. Silybin B (Silibinin B) is an orally active amyloid-β aggregation inhibitor and *ATR* pathway activator, that can cross the blood-brain barrier. Silybin B inhibits Aβ fibril formation and promotes amorphous aggregate formation, while activating the ATR-mediated DNA damage repair pathway and inhibiting JNK/p38 MAPK signaling. Silybin B can reduce Cisplatin (HY-17394)-induced neuronal DNA damage and apoptosis. Silybin B has anti-oxidative stress, cell cycle regulation and neuroprotective activities. Silybin B is mainly used in the study of Alzheimer's disease and Cisplatin chemotherapy-related neurotoxicity .

HY-B0255R

Adefovir dipivoxil (Standard) GS 0840 (Standard)	Structural Classification Natural Products Source classification Endogenous metabolite	Reference Standards HBV Reverse Transcriptase Orthopoxvirus Endogenous Metabolite
Adefovir dipivoxil (Standard) is the analytical standard of Adefovir dipivoxil. This product is intended for research and analytical applications. Adefovir dipivoxil is an orally active adenosine analog and Adefovir prodrug. Adefovir dipivoxil inhibits DNA synthesis, activates the *ATR* signaling pathway, and disrupts the KCTD12-CDK1 interaction. Adefovir dipivoxil has antiviral activity against PRV, HBV, and orthopoxviruses. Adefovir dipivoxil has inhibitory effects on both lamivudine-resistant and wild-type strains. Adefovir dipivoxil has antitumor activity against lung and colon cancer .

HY-N6954R

Garcinone C (Standard)	Structural Classification other families Xanthones Garcinia oblongifolia Champ. ex Benth. Guttiferae Source classification Phenols Polyphenols Plants	Reference Standards ATM/ATR STAT CDK Hedgehog
Garcinone C (Standard) is the analytical standard of Garcinone C. This product is intended for research and analytical applications. Garcinone C, a xanthone derivative, is a natural compound extracted from Garcinia oblongifolia that is used as an anti-inflammatory, astringency and granulation-promoting medicine, and has potential cytotoxic effects on certain cancers. Garcinone C stimulates the expression levels of *ATR* and 4E-BP1, arrests the cell cycle, inhibits cell viability of the human Nasopharyngeal carcinoma (NPC) cell lines CNE1, CNE2, HK1 and HONE1 in a time‑ and dose‑dependent manner through inhibition of Hedgehog signaling pathway. Garcinone C is orally active .

Cat. No.	Product Name	Chemical Structure

HY-101566S

Elimusertib-d3
Elimusertib-d3 (BAY 1895344-d3) is the deuterium labeled Elimusertib (BAY 1895344). Elimusertib is a potent, orally active and selective ATR inhibitor and has anti-tumor activity .

HY-N7046S

Silybin B-d3

Silybin B-d₃ (Silibinin B-d₃) is a deuterated Silybin B (HY-N7046). Silybin B (Silibinin B) is an orally active amyloid-β aggregation inhibitor and ATR pathway activator, that can cross the blood-brain barrier. Silybin B inhibits Aβ fibril formation and promotes amorphous aggregate formation, while activating the ATR-mediated DNA damage repair pathway and inhibiting JNK/p38 MAPK signaling. Silybin B can reduce Cisplatin (HY-17394)-induced neuronal DNA damage and apoptosis. Silybin B has anti-oxidative stress, cell cycle regulation and neuroprotective activities. Silybin B is mainly used in the study of Alzheimer's disease and Cisplatin chemotherapy-related neurotoxicity .

HY-W766548

Floxuridine-13C,15N2

Floxuridine- ¹³C, ¹⁵N₂ (5-Fluorouracil 2'-deoxyriboside- ¹³C, ¹⁵N₂) is the ¹³C- and ¹⁵N-labeled labeled Floxuridine (HY-B0097). Floxuridine (5-Fluorouracil 2'-deoxyriboside) is a pyrimidine analog and known as an oncology antimetabolite. Floxuridine inhibits Poly(ADP-Ribose) polymerase and induces DNA damage by activating the ATM and ATR checkpoint signaling pathways in vitro. Floxuridine is a extreamly potent inhibitor for S. aureus infection and induces cell apoptosis . Floxuridine has antiviral effects against HSV and CMV .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks